Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study

AIM: To determine the influence of high-efficacy disease modifying therapy (DMT) on the development of IgG SARS-CoV-2 antibody response in COVID-19 convalescent people with multiple sclerosis (pwMS). METHODS: Seventy-four pwMS taking high-efficacy DMTs (specifically natalizumab, fingolimod, alemtuzu...

Descripción completa

Detalles Bibliográficos
Autores principales: Habek, Mario, Jakob Brecl, Gregor, Bašić Kes, Vanja, Rogić, Dunja, Barun, Barbara, Gabelić, Tereza, Emeršič, Andreja, Horvat Ledinek, Alenka, Grbić, Nevena, Lapić, Ivana, Šegulja, Dragana, Đurić, Koraljka, Adamec, Ivan, Krbot Skorić, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366037/
https://www.ncbi.nlm.nih.gov/pubmed/34418815
http://dx.doi.org/10.1016/j.jneuroim.2021.577696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366037/
https://www.ncbi.nlm.nih.gov/pubmed/34418815
http://dx.doi.org/10.1016/j.jneuroim.2021.577696

Ejemplares similares